October 26, 2020

Positive Biomarker Efficacy Results from the ACTION-Galactosemia Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics

Post-Natal Galactitol Reduction is Associated with Normalization of CNS Phenotype in Animal Model of Galactosemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
American Society of Human Genetics (ASHG) 2020 Annual Meeting

September 23, 2020

AT-001: A Next Generation Aldose Reductase Inhibitor with Improved Potency, Selectivity and Specificity Protects from Cellular Damage Associated with Hyperglycaemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics

Addressing Safety and Specificity with Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
56th Annual Meeting of the European Association for the Study of Diabetes (EASD)

July 17-19, 2020

AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference

ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Galactosemia Foundation Conference

ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference

April 28, 2020
 
Applied Therapeutics Galactosemia Educational Symposium
Presented by Dr. Shoshana Shendelman, PhD & Dr. Riccardo Perfetti, MD, PhD
Moderated by Dr. Eva-Kozicz, MD, PhD

December 5-7, 2019

The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD

 
16th Global Cardio Vascular Clinical Trialists (CVCT) Forum
Washington, D.C.

American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas

September 16-20, 2019

AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy

55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain

September 13-16, 2019

Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy

Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA

October 15-16, 2018

A Novel Investigational Treatment In Preclinical Development For Galactosemia

NORD Rare Summit 2018
Washington, D.C.